other material
confidence high
sentiment positive
materiality 0.65
Matinas BioPharma: compassionate use patient complete resolution of rare fungal infection with MAT2203; Phase 3 planned
Matinas BioPharma Holdings, Inc.
- Patient treated with MAT2203 achieved complete clinical resolution of R. mucilaginosa infection after 6 months and regained use of foot.
- MAT2203 was well-tolerated with no renal adverse effects; patient's renal function improved and remained at baseline.
- Prior IV-amphotericin B was discontinued due to electrolyte abnormalities and toxicities; MAT2203 allowed outpatient monitoring.
- Company in final stages of planning Phase 3 program for MAT2203 with FDA.